Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company that develops and sells treatments for chronic endocrine and neurological diseases in the United States. The company offers three main commercial products. Recorlev treats endogenous hypercortisolemia in adults with Cushing's syndrome when surgery is not an option or has not been effective. Endogenous Cushing's syndrome is a rare endocrine disease caused by chronically high cortisol levels. Xeris Biopharma believes Recorlev has the potential to generate approximately $1 billion in annual net revenue at peak penetration in the United States. Gvoke, which includes Gvoke PFS, Gvoke HypoPen, and Gvoke Kit, is a ready-to-use, liquid-stable glucagon for treating severe hypoglycemia in pediatric and adult diabetes patients aged two years and above. The company estimates that over 14 million people in the United States are at high risk of severe hypoglycemia, and the total addressable market for this drug is approximately $5.0 billion in the United States. Keveyis is used to treat Primary Periodic Paralysis ("PPP"). Xeris Biopharma is also advancing XP-8121, a Phase 3-ready pipeline product that is a once-weekly subcutaneous ("SC") levothyroxine, utilizing its proprietary XeriSol technology.